Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hormone therapy controversy raises drug safety issues

17.02.2005


The history of hormone therapy drugs – once thought of as almost magic pills to keep women healthy, vital and young – shows why it is so important to conduct research studies to identify the risks and benefits of drugs, say researchers from Wake Forest University Baptist Medical Center.



"The hormone therapy debate is one more example of a larger issue: are the medications that doctors prescribe safe, and do the benefits outweigh any risks?" said Michelle Naughton, Ph.D., lead author of an article in the current issue of Journal of Social Issues.

The researchers review the 75-year history of hormone therapy (HT), including the Women’s Health Initiative (WHI) research that found increased risk of breast cancer, dementia, heart attacks and strokes in women taking combination hormone therapy – and increased risk of strokes in women taking estrogen alone. Naughton and co-authors Alison Snow Jones, Ph.D., and Sally Shumaker, Ph.D., all from Wake Forest Baptist, examine why there has been so much controversy surrounding the research findings and why many women and physicians are reluctant to accept the "lost promise" of HT. HT gained popularity in the 1950s and 1960s and is considered the best treatment for hot flashes and night sweats, which affect as many as two-thirds of menopausal women in the United States. But HT was also marketed as a way women could retain a youthful appearance and stave off the aging process and was prescribed for prevention of heart disease and dementia.


What began as a therapy for bothersome menopausal symptoms that dissipate within a couple of years for most women, became a potential long-term therapy for the prevention and treatment of three of the most common health issues for women – heart disease, dementia and osteoporosis, write the authors. "The intent was good," said Naughton, an associate professor of public health sciences. "There was some evidence showing the drugs might be beneficial for heart disease and dementia," she said, "but the WHI, a large-scale, scientifically conducted clinical trial, found otherwise."

Yet even after the WHI research, which the authors say the Food & Drug Administration found to be definitive, controversy continues about the study results and about use of HT. "In the face of such strong evidence that, at a minimum, HT does not help the postmenopausal woman beyond the osteoporosis benefit … and can actually harm the aging woman, why has there been resistance among many physicians and women to changing beliefs and practice patterns?" the researchers ask. They conclude that the conflicting interests of women, physicians and drug companies played a role in the popularity of HT (at one time it was one of the most commonly prescribed drugs in the United States) and fuel the continued controversy. They examine the issue from the perspectives of the various stakeholders. For women in the United States, who can expect to live a third or more of their lives after menopause, the stakes are a higher quality of life through their later years. In spite of evidence to the contrary, some women continue to believe that hormone therapy will provide them with better health, the authors said.

Health care professionals are influenced by the needs of their patients and well as information provided by drug manufacturers. In addition, they make their decisions based on years of clinical experience with HT, and may be reluctant to change prescribing patterns based on research findings that small numbers of study participants suffered adverse affects. "Physicians have learned that hormone therapy does provide relief to their patients," the authors write. "How can a drug that does such immediate good, and that appeared to do such long-term good, be so wrong?"

For hormone manufacturers, the stakes are millions of dollars in revenue. HT revenues were reported to be about $2.5 billion a year prior to the WHI study and sales fell to $266 million in the first quarter of 2004. Drug companies work to identify and promote drugs that offer the most promise to patients, but also must consider benefits to their stockholders.

Naughton said the HT controversy, as well as recent controversy surrounding Vioxx and other pain medications, raise issues about drug safety. "Implications of these controversies are the need for better mechanisms for establishing drug safety and monitoring, including the reporting of negative as well as positive trials of new or approved drugs," she said.

Karen Richardson | EurekAlert!
Further information:
http://www.wfubmc.edu

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Multiregional brain on a chip

16.01.2017 | Power and Electrical Engineering

New technology enables 5-D imaging in live animals, humans

16.01.2017 | Information Technology

Researchers develop environmentally friendly soy air filter

16.01.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>